Geode Capital Management LLC Cuts Stock Holdings in Context Therapeutics Inc. (NASDAQ:CNTX)

Geode Capital Management LLC lowered its stake in shares of Context Therapeutics Inc. (NASDAQ:CNTX) by 6.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 575,899 shares of the company’s stock after selling 42,275 shares during the quarter. Geode Capital Management LLC owned 0.77% of Context Therapeutics worth $1,129,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Y Intercept Hong Kong Ltd purchased a new stake in shares of Context Therapeutics during the third quarter valued at approximately $89,000. State Street Corp grew its stake in Context Therapeutics by 21.5% in the 3rd quarter. State Street Corp now owns 111,907 shares of the company’s stock valued at $219,000 after purchasing an additional 19,800 shares during the period. Nantahala Capital Management LLC purchased a new stake in shares of Context Therapeutics during the 2nd quarter valued at $3,881,000. Driehaus Capital Management LLC bought a new stake in shares of Context Therapeutics during the 2nd quarter worth $4,527,000. Finally, Blue Owl Capital Holdings LP purchased a new position in shares of Context Therapeutics in the 2nd quarter worth about $10,348,000. 14.03% of the stock is currently owned by institutional investors.

Context Therapeutics Price Performance

NASDAQ:CNTX opened at $1.21 on Friday. Context Therapeutics Inc. has a one year low of $0.89 and a one year high of $2.75. The company’s 50-day simple moving average is $1.50 and its 200 day simple moving average is $1.93. The firm has a market capitalization of $90.75 million, a P/E ratio of -1.33 and a beta of 2.10.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.11). On average, equities research analysts expect that Context Therapeutics Inc. will post -0.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on CNTX. D. Boral Capital began coverage on shares of Context Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $9.00 price target for the company. Citizens Jmp raised Context Therapeutics to a “strong-buy” rating in a research report on Wednesday. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Context Therapeutics in a research note on Monday, September 23rd. Finally, JMP Securities initiated coverage on Context Therapeutics in a research note on Wednesday. They set an “outperform” rating and a $4.00 price target for the company. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $6.33.

Context Therapeutics Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.